Clinical trial NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies
Official title: A Phase Ia/b Clinical Study on Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Protein Degradation Agent HSK29116 in Subjects With Relapsed or Refractory B-Cell Malignancy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Relapsed/Refractory B-Cell Malignancies
Lead sponsor: Haisco Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-04-27
Enrollment: 156
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of HSK29116 in patients with advanced B-cell malignancies.

Detailed description: This study is divided into 2 parts. Phase 1a is a dose escalation to evaluate the safety and tolerability of HSK29116 in adult patients with relapsed/refractory (R/R) B-cell malignancies, who have required and received at least 2 prior systemic therapy and for whom no other therapies are known to provide clinical benefit. Phase 1b will investigate the efficacy of HSK29116 at the dose selected in Phase 1a in up to 3 cohorts of patients with R/R B-cell malignancy indications who have received at least 2 prior systemic therapy：

Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)； Mantle Cell Lymphoma (MCL)； Other B-cell malignancies (they will be selected according to the preliminary results of Phase Ia)

Eligibility criteria: Inclusion Criteria:

* Males or females, of any race, aged ≥ 18 years.
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0- 2.
* Sufficient bone marrow function, hepatic function and Coagulation function.
* Patients must have measurable disease per disease-specific response criteria.
* Have histologically confirmed R/R CLL,SLL,MCL,Non-GCB DLBCL,FL(grade 1- 3a),MZL,WM.
* Received at least 2 prior systemic therapy and have no other therapies known to provide clinical benefit.
* After the most recent treatment regimen, it is confirmed that PR has not been achieved, or there is confirmed progressive disease.
* Must require systemic therapy.
* The pregnancy test (urine or serum) of female subjects of childbearing potential shall be negative before enrollment.
* Female subjects of childbearing potential and fertile male subjects shall adopt one of the following highly effective contraception measures during the entire study and within 90 days after the study treatment is ended: abstinence, intrauterine device, or hormonal contraceptives beginning at least 3 months before the first dose of IMP.Male subjects are prohibited from donating sperm from the start of study treatment to 90 days after the end of treatment.

Exclusion Criteria:

* Subjects with central nervous system involvement.
* Subjects with histopathological transformation.
* Receipt of allogeneic hematopoietic stem cell transplantation ≤ 180 days before the start of study treatment administration on Cycle 1, Day 1, unless the subject is no longer on immunosuppressant medication. History of autologous hematopoietic stem cell transplantation within 12 weeks (84 days) before the start of study treatment.
* Continuous immunosuppressive therapy, including systemic (such as intravenous or oral) treatment with corticosteroids for the underlying diseases within 2 weeks before the first dose.
* Patients who have received BTKis, tyrosine kinase inhibitors or other targeted small molecule drugs for anti-tumor treatment within 7 days (or 5 half-lives, whichever is shorter) before initiation of study drug; or patients who have received any biological and/or immune-based anti-tumor treatment, including investigational treatment (including but not limited to monoclonal antibody therapy and/or anti-tumor vaccine) within 4 weeks (or 5 half-lives, whichever is shorter); or patients who have received systemic chemotherapy, radiotherapy or traditional Chinese medicines with anti-tumor effect (traditional Chinese medicines with anti-tumor indications specified in the package insert) within 2 weeks (or 5 half-lives, whichever is shorter).
* Previously developed toxicity due to anticancer treatment that did not resolve to Grade ≤ 1 (as per NCI-CTCAE 5.0), except for AEs not constituting a safety risk as assessed by the investigator.
* A history of other malignant tumors within 2 years before enrollment, except for basal cell carcinoma or skin squamous cell carcinoma having been adequately treated, or without disease for ≥ 2 years or with other types of cancer with the survival time of greater than 2 years. Subjects with breast or prostate cancer who are on maintenance hormonal therapies following therapeutic procedures with curative intent are permitted.
* Uncontrolled systemic active infections, or other infections or still on intravenous anti-infection treatment.
* Underwent major surgery in the past 4 weeks.
* Known infection with human immunodeficiency virus, or serologic status reflecting active hepatitis B or C infection.
* Subjects with severe cardiovascular diseases within 6 months before screening.
* Left Ventricular Ejection Fraction \< 50% based on either echocardiogram or multigated acquisition (MUGA) scan.
* QTcF ≥ 450 msecs for males and QTcF ≥ 470 msec for females or other significant ECG abnormalities.
* Clinically significant gastrointestinal abnormalities that may affect the intake, transport, or absorption of drugs.
* Requiring or received anticoagulant therapy with warfarin or equivalent vitamin K antagonists (such as phenprocoumon) within 7 days before the first study treatment.
* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura. Known history of bleeding diathesis.
* A history of stroke or intracranial hemorrhage within 6 months before the first study treatment.
* Use of CYP3A4 inhibitor or inducer within 7 days before the first study treatment, or using of sensitive substrates metabolized by CYP3A4/CYP2B6.

Primary outcomes:
measure: Number of Participants with Protocol Specified Dose-Limiting Toxicities
timeFrame: 1 year
measure: To establish the MTD and/or recommended Phase 1b dose of HSK29116
timeFrame: 1 year
measure: Number of Participants with Adverse Events and Clinical Laboratory Abnormalities
timeFrame: Up to 3 years
Secondary outcomes:
measure: Pharmacokinetic(PK) Profile of HSK29116: Maximum Serum Concentration
timeFrame: At the end of Cycle 1 (each cycle is 28 days)
measure: Overall response rate(ORR) as assessed by the Investigator
timeFrame: Up to 3 Years
measure: Duration of response(DoR) as assessed by the Investigator
timeFrame: Up to 3 Years
measure: Progression-free survival(PFS) as assessed by the Investigator
timeFrame: Up to 3 Years
measure: Time to response(TTR) as assessed by the Investigator
timeFrame: Up to 3 Years
Other outcomes:
Locations:
city: Perth
country: Australia
facility: One Clinical Research
city: Guangzhou
country: China
facility: NANFANG Hospital
state: Guangdong
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
city: Changsha
country: China
facility: Hunan Cancer Hospita
state: Hunan
city: Nanjing
country: China
facility: Jiangsu Province Hospital
state: Jiangsu
city: Jinan
country: China
facility: Shandong Provincial Hospital
state: Shandong
city: Hangzhou
country: China
facility: The Second Affiliated Hospital Zhejiang University School of Medicine
state: Zhejiang
city: Hanzhou
country: China
facility: The First Affiliated Hospital, Zhejiang University School of Medicine
state: Zhejiang
Study officials:
affiliation: Haisco Pharmaceutical Group Co., Ltd.
name: Shufang Zhang
role: STUDY_DIRECTOR
References: